Keyphrases
Receptor Subtypes
100%
GIP Receptor
100%
Internalization Efficiency
100%
Residence Time
100%
Receptor Desensitization
100%
Long-term Disability
100%
Type 2 Diabetes Mellitus (T2DM)
37%
Type 2 Diabetic Patients
25%
Insulinotropic Effects
25%
Glucagon-like peptide-1 (GLP-1)
25%
Functional Impairment
12%
Blood Sugar
12%
COS-7 Cells
12%
Arrestin
12%
Ligand Binding Kinetics
12%
Basal Activity
12%
Type 2 Diabetes Prevention
12%
In Silico Modeling
12%
Dissociation Rate
12%
Desensitization
12%
Kd Values
12%
Low Bone Mineral Density
12%
Competition Binding
12%
Bone Metabolism
12%
Gi Signaling
12%
Association Rate
12%
Blood Glucose
12%
Koff
12%
Immunology and Microbiology
Retention Time
100%
Receptor down Regulation
100%
Internalization
100%
Agonist
100%
Binding Competition
16%
Bone Density
16%
Glucose Blood Level
16%
Retina S Antigen
16%
Ligand Binding
16%
Downregulation
16%
Binding Kinetics
16%
Association Rate Constant
16%
cAMP Signaling
16%
Dissociation Rate Constant
16%
Bone Remodeling
16%
Biochemistry, Genetics and Molecular Biology
Internalization
100%
Receptor down Regulation
100%
Agonist
100%
Retention Time
100%
Gastric Inhibitory Polypeptide
100%
Glucagon-Like Peptide-1
12%
Downregulation
6%
Dissociation Rate Constant
6%
cAMP Signaling
6%
Binding Competition
6%
Glucose Blood Level
6%
Binding Kinetics
6%
Association Rate Constant
6%
Arrestin
6%
Bone Density
6%
Bone Remodeling
6%
Ligand Binding
6%
Neuroscience
Gastric Inhibitory Polypeptide
100%
Agonist
100%
Receptor
100%
Receptor down Regulation
100%
Internalization
100%
Diabetes Mellitus
18%
Glucagon-Like Peptide-1
12%
Binding Competition
6%
cAMP Signaling
6%
Binding Kinetics
6%
Retina S Antigen
6%
Metabolic Pathway
6%
Ligand Binding
6%
Medicine and Dentistry
Receptor
100%
Internalization
100%
Gastric Inhibitory Polypeptide
100%
Receptor down Regulation
100%
Maturity Onset Diabetes of the Young
18%
Glucagon Like Peptide 1
12%
Patient with Type 2 Diabetes
12%
Binding Competition
6%
cAMP Signaling
6%
Retina S Antigen
6%
Desensitization
6%
In Silico
6%
Blood Glucose
6%
Bone Remodeling
6%
Binding Kinetics
6%
Ligand Binding
6%
Downregulation
6%
Fracture
6%
Functional Disease
6%
Bone Density
6%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
100%
Receptor
100%
Desensitization
100%
Non Insulin Dependent Diabetes Mellitus
18%
Glucagon-Like Peptide-1
12%
Functional Disease
6%
Retina S Antigen
6%
Fracture
6%
Endogenous Agonist
6%